A concerted effort to collect and bank tissues and biologic fluids from the upper respiratory tract has been an ongoing effort since 1990 under the direction of the Pathology Core leader. Initially, specimen collection primarily targeted overtly malignant carcinomas. Over time, the focus of specimen collection has shifted to tissues and biologic fluids representing much earlier stages along the tumor progression pathway and specimens from control patients without head and neck cancer. The availability of these tissues and cells has contributed to the work of many of the investigators participating in the SPORE, resulting over the years in significant discoveries with high translational impact and numerous peer-reviewed publications. The Pathology Core will continue to: 1) collect, store, process and distribute tissues and biologic fluids for translational research without compromise of patient care;2) provide well-characterized tumors with respect to site of origin, Worid Health Organization histologic subtype, differentiation, and fraction of neoplastic and stromal tissues;3) provide normal control tissue in addition to neoplasms;4) process and store tissues to address the requirements of all SPORE investigators;5) include neoplasms with a wide range of biologic potential (e.g. normal, dysplasia, carcinoma sequence);6) perpetuate tumor growth and expand tumor availability by xenografting tumors into immunodeficient mice;7) collect blood and exfoliated cells (e.g. oral rinses/oral brushes) from pertinent patients for the SPORE projects;8) provide the specimens in a timely fashion;and 9) provide well-defined mechanisms for prioritization of the distribution of requested resources to investigators within and external to the Johns Hopkins SPORE.
The availability of high quality and well characterized human specimens is central and vital to translational research. The provisions of these specimens is imperative to the success of the SPORE projects.
|Li, Ryan; Faden, Daniel L; Fakhry, Carole et al. (2015) Clinical, genomic, and metagenomic characterization of oral tongue squamous cell carcinoma in patients who do not smoke. Head Neck 37:1642-9|
|Gaykalova, Daria A; Mambo, Elizabeth; Choudhary, Ashish et al. (2014) Novel insight into mutational landscape of head and neck squamous cell carcinoma. PLoS One 9:e93102|
|Dýýsouza, Gypsyamber; Carey, Thomas E; William Jr, William N et al. (2014) Epidemiology of head and neck squamous cell cancer among HIV-infected patients. J Acquir Immune Defic Syndr 65:603-10|
|Wu, Chao-Yi; Yang, Li-Hua; Yang, Huang-Yu et al. (2014) Enhanced cancer radiotherapy through immunosuppressive stromal cell destruction in tumors. Clin Cancer Res 20:644-57|
|Bishop, Justin A; Yonescu, Raluca; Batista, Denise et al. (2014) Mucoepidermoid carcinoma does not harbor transcriptionally active high risk human papillomavirus even in the absence of the MAML2 translocation. Head Neck Pathol 8:298-302|
|Sun, Wenyue; Gaykalova, Daria A; Ochs, Michael F et al. (2014) Activation of the NOTCH pathway in head and neck cancer. Cancer Res 74:1091-104|
|Fakhry, Carole; Gillison, Maura L; D'Souza, Gypsyamber (2014) Tobacco use and oral HPV-16 infection. JAMA 312:1465-7|
|Izumchenko, Evgeny; Chang, Xiaofei; Michailidi, Christina et al. (2014) The TGF?-miR200-MIG6 pathway orchestrates the EMT-associated kinase switch that induces resistance to EGFR inhibitors. Cancer Res 74:3995-4005|
|Bishop, Justin A; Yonescu, Raluca; Batista, Denise et al. (2014) Glandular odontogenic cysts (GOCs) lack MAML2 rearrangements: a finding to discredit the putative nature of GOC as a precursor to central mucoepidermoid carcinoma. Head Neck Pathol 8:287-90|
|Bishop, Justin A; Antonescu, Cristina R; Westra, William H (2014) SMARCB1 (INI-1)-deficient carcinomas of the sinonasal tract. Am J Surg Pathol 38:1282-9|
Showing the most recent 10 out of 45 publications